Melanoma

>

Latest News

Image of camera taking picture of skin.
Opdivo and Yervoy May Improve Survival for Resected Stage 3/4 Melanoma

October 31st 2024

Patients with resected stage 3 or 4 melanoma treated with immune-oncology agents demonstrated significantly higher cure rates compared to those treated with placebo.

Image of a doctor examining a patient's skin.
Longer Time Until Recurrence Associated With Better Melanoma Outcomes

October 2nd 2024

Photo of camera capturing skin.
Long-Term Study Data Support Keytruda as Standard of Care for Advanced Melanoma

October 1st 2024

FDA text.
Oncology Drugs Approved by the FDA in September 2024

October 1st 2024

Picture of the back of a man.
Survival Benefit Continues at 10 Years From Opdivo Either Alone or With Yervoy in Advanced Melanoma

September 25th 2024

More News